Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification

The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment.

RHAPSODY plans to characterise those patients who i) progress to T2D diagnosis and ii) those T2D patients who eventually progress onto treatment by insulin.